News › Industry News, News

ITC Favors Allergan Partner Medytox Over Daewoong in Botulinum Toxin Strain Dispute

July 10, 2020

The U.S. International Trade Commission (ITC) has sided with South Korean drugmaker Medytox Inc. in a dispute, saying its local rival Daewoong Pharmaceutical Co. stole trade secrets on a botulinum toxin strain, industry officials here said Tuesday.
In its preliminary verdict, the ITC also advised that imports of Daewoong Pharmaceutical’s botulinum toxin products be banned in the United States over the next 10 years.Read more at the Yonhap News Agency >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Massachusetts Med Spa Owner Pleads Guilty in Federal Counterfeit Injection Case
    • Merz Aesthetics’ Radiesse Receives FDA Approval for Décolleté Wrinkles
    • New Book “Get Found, Get Booked” Reveals a Smarter, Ethical Approach to Marketing for Med Spas and Wellness Practices
    • Bill Regulating Indiana Med Spas Has Passed: What You Need to Know and Why Collective Advocacy Matters
    • Growth, Capital and Control: Navigating Private Equity in Aesthetics